# IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)

> **NCT02232425** · PHASE2 · COMPLETED · sponsor: **Ixchelsis Limited** · enrollment: 88 (actual)

## Conditions studied

- Premature Ejaculation

## Interventions

- **DRUG:** IX-01
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02232425
- **Lead sponsor:** Ixchelsis Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2020-08-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02232425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02232425, "IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02232425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*